Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 401

1.

Dosing Guidance for Intravenous Colistin in Critically Ill Patients.

Nation RL, Garonzik SM, Thamlikitkul V, Giamarellos-Bourboulis EJ, Forrest A, Paterson DL, Li J, Silveira FP.

Clin Infect Dis. 2016 Dec 23. doi: 10.1093/cid/ciw839. [Epub ahead of print] No abstract available.

PMID:
28184480
2.

Can ceftazidime/avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae?

Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG Jr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA.

Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02243-16. doi: 10.1128/AAC.02243-16. [Epub ahead of print]

PMID:
28167541
3.

China's antibiotic resistance problems.

Paterson DL, van Duin D.

Lancet Infect Dis. 2017 Jan 27. pii: S1473-3099(17)30053-1. doi: 10.1016/S1473-3099(17)30053-1. [Epub ahead of print] No abstract available.

PMID:
28139428
4.

Risk factors for relapse or persistence of bacteraemia caused by Enterobacter spp.: a case-control study.

Harris PN, Peri AM, Pelecanos AM, Hughes CM, Paterson DL, Ferguson JK.

Antimicrob Resist Infect Control. 2017 Jan 21;6:14. doi: 10.1186/s13756-017-0177-0.

5.

Long-term mortality following Pseudomonas aeruginosa bloodstream infection.

McCarthy KL, Paterson DL.

J Hosp Infect. 2017 Mar;95(3):292-299. doi: 10.1016/j.jhin.2016.11.014.

PMID:
28089143
6.

Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae.

Palacios-Baena ZR, Gutiérrez-Gutiérrez B, De Cueto M, Viale P, Venditti M, Hernández-Torres A, Oliver A, Martínez-Martínez L, Calbo E, Pintado V, Gasch O, Almirante B, Antonio Lepe J, Pitout J, Akova M, Peña-Miralles C, Schwaber MJ, Tumbarello M, Tacconelli E, Origüen J, Prim N, Bou G, Giamarellou H, Bermejo J, Hamprecht A, Pérez F, Almela M, Lowman W, Hsueh PR, Navarro-San Francisco C, Torre-Cisneros J, Carmeli Y, Bonomo RA, Paterson DL, Pascual Á, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Group..

J Antimicrob Chemother. 2017 Jan 6. pii: dkw513. doi: 10.1093/jac/dkw513. [Epub ahead of print]

PMID:
28062685
7.

Dosing guidance for intravenous colistin in critically-ill patients.

Nation RL, Garonzik SM, Thamlikitkul V, Giamarellos-Bourboulis EJ, Forrest A, Paterson DL, Li J, Silveira FP.

Clin Infect Dis. 2016 Dec 23. pii: ciw839. doi: 10.1093/cid/ciw839. [Epub ahead of print]

PMID:
28011614
8.

Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis.

Righi E, Peri AM, Harris PN, Wailan AM, Liborio M, Lane SW, Paterson DL.

J Antimicrob Chemother. 2016 Dec 20. pii: dkw459. doi: 10.1093/jac/dkw459. [Epub ahead of print]

PMID:
27999023
9.

The molecular epidemiology of Pseudomonas aeruginosa bloodstream infection isolates in a non-outbreak setting.

McCarthy KL, Kidd TJ, Paterson DL.

J Med Microbiol. 2016 Dec 19. doi: 10.1099/jmm.0.000413. [Epub ahead of print]

PMID:
27995865
10.

Enhancement of antibiotic-activity through complexation with metal ions - Combined ITC, NMR, enzymatic and biological studies.

Möhler JS, Kolmar T, Synnatschke K, Hergert M, Wilson LA, Ramu S, Elliott AG, Blaskovich MA, Sidjabat HE, Paterson DL, Schenk G, Cooper MA, Ziora ZM.

J Inorg Biochem. 2017 Feb;167:134-141. doi: 10.1016/j.jinorgbio.2016.11.028.

PMID:
27984786
11.

Community-acquired Pseudomonas aeruginosa bloodstream infection: a classification that should not falsely reassure the clinician.

McCarthy KL, Paterson DL.

Eur J Clin Microbiol Infect Dis. 2016 Dec 9. [Epub ahead of print]

PMID:
27942878
12.

Identification of IncA/C Plasmid Replication and Maintenance Genes and Development of a Plasmid Multilocus Sequence Typing Scheme.

Hancock SJ, Phan MD, Peters KM, Forde BM, Chong TM, Yin WF, Chan KG, Paterson DL, Walsh TR, Beatson SA, Schembri MA.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01740-16. doi: 10.1128/AAC.01740-16.

PMID:
27872077
13.

Central nervous system nocardiosis in Queensland: A report of 20 cases and review of the literature.

Rafiei N, Peri AM, Righi E, Harris P, Paterson DL.

Medicine (Baltimore). 2016 Nov;95(46):e5255. Review.

14.

Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition.

Harris PN, McNamara JF, Lye DC, Davis JS, Bernard L, Cheng AC, Doi Y, Fowler VG Jr, Kaye KS, Leibovici L, Lipman J, Llewelyn MJ, Munoz-Price S, Paul M, Peleg AY, Rodríguez-Baño J, Rogers BA, Seifert H, Thamlikitkul V, Thwaites G, Tong SY, Turnidge J, Utili R, Webb SA, Paterson DL.

Clin Microbiol Infect. 2016 Nov 1. pii: S1198-743X(16)30512-2. doi: 10.1016/j.cmi.2016.10.023. [Epub ahead of print] Review.

PMID:
27810466
15.

Return to sender: the need to re-address patient antibiotic allergy labels in Australia and New Zealand.

Trubiano JA, Worth LJ, Urbancic K, Brown TM, Paterson DL; Australasian Society for Infectious Diseases Clinical Research Network., Lucas M; Australasian Society of Clinical Immunology and Allergy., Phillips E.

Intern Med J. 2016 Nov;46(11):1311-1317. doi: 10.1111/imj.13221.

16.

Comparison of Clostridium difficile Ribotypes Circulating in Australian Hospitals and Communities.

Furuya-Kanamori L, Riley TV, Paterson DL, Foster NF, Huber CA, Hong S, Harris-Brown T, Robson J, Clements AC.

J Clin Microbiol. 2016 Dec 28;55(1):216-225. doi: 10.1128/JCM.01779-16.

PMID:
27807147
17.

Asymptomatic Clostridium difficile colonization in two Australian tertiary hospitals, 2012-2014: prospective, repeated cross-sectional study.

Furuya-Kanamori L, Clements AC, Foster NF, Huber CA, Hong S, Harris-Brown T, Yakob L, Paterson DL, Riley TV.

Clin Microbiol Infect. 2017 Jan;23(1):48.e1-48.e7. doi: 10.1016/j.cmi.2016.08.030.

PMID:
27615716
18.

Detection of carbapenemase activity in Enterobacteriaceae using LC-MS/MS in comparison with the neo-rapid CARB kit using direct visual assessment and colorimetry.

Huber CA, Sidjabat HE, Zowawi HM, Kvaskoff D, Reed S, McNamara JF, McCarthy KL, Harris P, Toh B, Wailan AM, Paterson DL.

J Microbiol Methods. 2016 Dec;131:68-72. doi: 10.1016/j.mimet.2016.10.005.

19.

A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae.

Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Pintado V, Doi Y, Tuon FF, Karaiskos I, Machuca I, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, Pérez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J; Investigators from the REIPI/ESGBIS/INCREMENT Group..

Mayo Clin Proc. 2016 Oct;91(10):1362-1371. doi: 10.1016/j.mayocp.2016.06.024.

PMID:
27712635
20.

Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.

Popejoy MW, Paterson DL, Cloutier D, Huntington JA, Miller B, Bliss CA, Steenbergen JN, Hershberger E, Umeh O, Kaye KS.

J Antimicrob Chemother. 2017 Jan;72(1):268-272.

PMID:
27707990
Items per page

Supplemental Content

Loading ...
Support Center